Literature DB >> 12459730

Bloodborne biomolecular markers in prostate cancer development and progression.

Robert A Bok1, Eric J Small.   

Abstract

Prostate cancer is notoriously difficult to treat, which makes its early detection a priority. Biomarkers have been used to diagnose and monitor prostate cancer for more than 50 years, and the discovery of the serum marker prostate-specific antigen (PSA) significantly altered the detection and management of prostate cancer. But imperfect correlation with cancer hinders the usefulness of PSA. The elucidation and validation of new biological markers of prostate cancer should aid detection, and improve the application of the available therapeutics.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12459730     DOI： 10.1038/nrc951

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  11 in total

1.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

2.  The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells.

Authors:  Kohei Hashimoto; Yuki Kyoda; Toshiaki Tanaka; Toshihiro Maeda; Ko Kobayashi; Kohsuke Uchida; Hiroshi Kitamura; Koichi Hirata; Taiji Tsukamoto; Naoya Masumori
Journal:  Lab Invest       Date:  2015-01-12       Impact factor: 5.662

3.  Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

4.  An electrochemical immunosensor for the prostate specific antigen based on the use of reduced graphene oxide decorated with gold nanoparticles.

Authors:  Parnaz Assari; Amir Abbas Rafati; Azizallah Feizollahi; Roghayeh Asadpour Joghani
Journal:  Mikrochim Acta       Date:  2019-06-29       Impact factor: 5.833

Review 5.  Molecular and genetic prognostic factors of prostate cancer.

Authors:  Arnab Chakravarti; Gary Guotang Zhai
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

6.  Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation.

Authors:  Yuanjie Niu; Shuyuan Yeh; Hiroshi Miyamoto; Gonghui Li; Saleh Altuwaijri; Jianqun Yuan; Ruifa Han; Tengxiang Ma; Hann-Chorng Kuo; Chawnshang Chang
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

7.  REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer.

Authors:  Yi-Ting Chang; Tzu-Ping Lin; Mel Campbell; Chin-Chen Pan; Shu-Hui Lee; Hsin-Chen Lee; Muh-Hwa Yang; Hsing-Jien Kung; Pei-Ching Chang
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

8.  Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer.

Authors:  V Michalaki; K Syrigos; P Charles; J Waxman
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

Review 9.  Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.

Authors:  Pedro C Rodriguez; Belinda Sanchez
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

10.  Locus-specific gene repositioning in prostate cancer.

Authors:  Marc Leshner; Michelle Devine; Gregory W Roloff; Lawrence D True; Tom Misteli; Karen J Meaburn
Journal:  Mol Biol Cell       Date:  2015-11-12       Impact factor: 4.138
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.